linjc16/ctgov huggingface dataset:
Socket Shield Technique Versus Early Implant Placement With Contour Augmentation

Study Overview
=================
Brief Summary
-----------------
comparing socket shield technique with early implant placement with contour augmentation in preserving the bone contour

Detailed Description
-----------------
comparing immediate implant placement with socket shield technique and final crown after 3 months with extraction and after 4 to 8 weeks implant placement with contour bone augmentation then after 3 to 4 months final crown delivery

Official Title
-----------------
Socket Shielding in Immediate Versus Early Implant Placement With Contour Augmentation of Fresh Extraction Sockets in the Esthetic Zone. A Randomized Pilot Clinical Study.

Conditions
-----------------
Bone Loss, Bone Resorption

Intervention / Treatment
-----------------
* Procedure: contour augmentation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-restorable maxillary teeth in the esthetic zone Intact adjacent teeth Adequate palatal and apical bone that allows achieving implant primary stability. Type I socket ≥18 years ≤ 60 years Systemically healthy patients Exclusion Criteria: Extraction sockets with acute or chronic infection or with adjacent infected teeth Heavy Smokers > than 10 cigarettes daily Cancer patients undergoing radiotherapy or chemotherapy during or within the last 6 months. Unmotivated patients to maintain adequate oral hygiene to follow up. Patients with physical disabilities that could affect follow up.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: socket shield technique<br>immediate implant placement with socket shield technique | Procedure: contour augmentation<br>* early implant placement with contour bone augmentation<br>|
| Active Comparator: contour augmentation<br>early implant placement with contour bone augmentation | Procedure: contour augmentation<br>* early implant placement with contour bone augmentation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| facial bone thickness | using superimposed CBCT images | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| facial bone height changes | using superimposed CBCT images | 12 months | 
| Soft tissue height changes | using superimposed intraoral scans | 12 months |
Prognosis of SRD Patients in the ICU

Study Overview
=================
Brief Summary
-----------------
Critically ill systemic rheumatic disease (SRD) patients have benefited from better provision of rheumatic and critical care in recent years. Recent comprehensive data regarding in-hospital mortality and most importantly long-term outcome are scarce. The aim of this study is to assess short and long-term outcome of patients with SRD admitted to the ICU in a retrospective cohort study (2006 - 2016).

Official Title
-----------------
One-year Outcome of Critically Ill Patients With Systemic Rheumatic Disease: a Multicenter Cohort Study

Conditions
-----------------
Systemic Rheumatic Diseases, Intensive Care Unit, Corticosteroids

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: All consecutive SRD patients admitted to ICUs during the study period at least one urine sample Exclusion criteria: Age < 18 years Persons under protection Paritcipation rejections Admition to the ICU after scheduled surgery or trauma or suicide attempt unrelated to neurological involvement of SRD Cancer treated with chemotherapy within a month before ICU admission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality rate in the ICU associated risk factors | Mortality rate in the ICU associated risk factors | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality rate in the hospital and one-year after ICU admission and associated risk factors | Mortality rate in the hospital and one-year after ICU admission and associated risk factors | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
outcomes, prognostic factors
Evaluation for Restoration of Erectile Dysfunction After Cardioversion Treatment Trial

Study Overview
=================
Brief Summary
-----------------
Erectile and Cognitive function by using the questionnaire and assessment form before sinus conversion

Detailed Description
-----------------
Sinus conversion by electrical cardioversion increase cardiac output and systemic perfusion. According to recent reports, maintenance of sinus rhythm increase systemic perfusion which leads to improve renal function. Therefore, we hypothesized that sinus conversion of patients with atrial fibrillation will increase systemic perfusion which might improve the erectile dysfunction and cognitive dysfunction.

Official Title
-----------------
Evaluation for Restoration of Erectile Dysfunction After Cardioversion Treatment Trial

Conditions
-----------------
Erectile Dysfunction

Intervention / Treatment
-----------------
* Other: Erectile dysfunction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled to electrical cardioversion Exclusion Criteria: Patients have taken any medication for erectile dysfunction or who have got any operation already or are scheduled to do. More than moderate degree of cognitive dysfunction
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Restoration of Erectile dysfunction<br>The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm. | Other: Erectile dysfunction<br>* The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm. The changes of cognitive function by using validated assessment form-The Montreal Cognitive assessment (MoCA) 1 year after conversion to sinus rhythm.<br>* Other names: official questionnaire;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The changes of erectile function | The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm. | Erectile dysfunction 1 year after conversion to sinus rhythm. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The changes of cognitive function | The changes of cognitive function by using validated assessment form-The Montreal Cognitive Assessement(MoCA) 1 year after conversion to sinus rhythm | cognitive dysfunction 1 year after conversion to sinus rhythm | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Erectile dysfunction, cognitive function
Offering Nicotine Patches to All Households in a Municipality With High Smoking Rates

Study Overview
=================
Brief Summary
-----------------
One municipality with high smoking rates will be selected. A coupon for free-of-charge nicotine patches will be sent to each household. Reductions in the number of people smoking in the chosen municipality from before to after the NRT distribution will be estimated

Detailed Description
-----------------
A coupon offering five weeks of free nicotine patches will be mailed to every household in a small municipality with elevated smoking rates. Up to 800 participants (one per household) will be able to redeem their coupon online or by phone, and receive nicotine patches via postal mail. Participants will be asked to complete a baseline survey containing items relevant to predicting smoking cessation. Participants will be asked to complete a six-month follow-up survey to assess changes in smoking status. Research Question: Will the concentrated distribution of nicotine patches in a region of high smoking rates lead to large reductions in smoking rates?

Official Title
-----------------
Offering Nicotine Patches to All Households in a Municipality With High Smoking Rates: Test of an Idea to Promote Large Increases in Tobacco Cessation

Conditions
-----------------
Tobacco Use Cessation

Intervention / Treatment
-----------------
* Drug: Nicotine patch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: speak and understand English 18 years or older smoke 10 or more cigarettes per day for at least 3 months Exclusion Criteria: health contraindications for using nicotine patches without supervision of a doctor (e.g. allergy to tape, pregnant or intending to become pregnant, currently breastfeeding, serious heart or circulation problems not including high blood pressure)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nicotine patch|Nicotine transdermal patches as per product monograph|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 30-day pint prevalence abstinence | No smoking of cigarettes in the past 30 days | 6 months |
Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to compare the efficacy and safety of Timolol 0.5% solution to Brinzolamide 1% each given twice daily when added to Travoprost 0.004% given each evening.

Official Title
-----------------
Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension

Conditions
-----------------
Primary Open-angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma

Intervention / Treatment
-----------------
* Drug: Brinzolamide 1% added to Travoprost 0.004%


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are treated with any prostaglandin analogue monotherapy (excluding unoprostone) and who have an intraocular pressure between 19 and 32 mmHg at 08:00 hours. Exclusion Criteria: Under 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Brinzolamide 1% added to Travoprost 0.004%|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean diurnal intraocular pressure at month 3 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Individual intraocular pressures measured at 08:00, 12:00 and 16:00 at month 3. |  |  | 
| Reduction from baseline in mean diurnal intraocular pressure and individual timepoints. |  |  | 
| Visual acuity, Slit lamp biomicroscopy and adverse events during 3 months. |  |  |
The Role of Point-of-care Polymerase Chain Reaction in Managing Nosocomial Pneumonia

Study Overview
=================
Brief Summary
-----------------
The study compares a device that is used for the detection of bacteria and MDR pathogens from skin, soft tissue and nose with the gold-standard (microbiological lab). It is a novel use for this device because it has been used in samples from the lower-respiratory tract.

Detailed Description
-----------------
The purpose of this study is to find out if a POC-PCR device can be use in the diagnosis of hospital acquired pneumonia and ventilation-associated pneumonia.

Official Title
-----------------
The Role of Point-of-care Polymerase Chain Reaction in Managing Nosocomial Pneumonia

Conditions
-----------------
Nosocomial Pneumonia

Intervention / Treatment
-----------------
* Diagnostic Test: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients that are admitted for at least 48 hours radiological findings typical for pneumonia signs of infection Exclusion Criteria: patient or patient relatives doesn't accept to enter the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: no intervention|no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the sensibility and specificity of the device GeneXpert in diagnosis of pneumonia | Comparison between device and gold standard | 4 years | 
| Utility of POC-PCR in managing pneumonia | Decision making in pneumonia management | 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
polymerase chain reaction
An Observational Study of Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab)

Study Overview
=================
Brief Summary
-----------------
This observational study will evaluate the glucocorticoid sparing effect after 12 months of treatment with RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected for 12 months after the initiation of treatment with RoActemra/Actemra from patients who had been on treatment with >5 mg prednisone or equivalent for at least 3 months .

Official Title
-----------------
Evaluation of Glucocorticoid Sparing Effect in Patients Receiving RoActemra® for Rheumatoid Arthritis in Real Life.

Conditions
-----------------
Rheumatoid Arthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients, >/= 18 years of age Patients with rheumatoid arthritis for whom the rheumatologist decided to introduce RoActemra Patients taking more than 5 mg/day of oral prednisone (or equivalent) for at least 3 months Exclusion Criteria: Participation in a clinical trial in rheumatoid arthritis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients receiving </= 5 mg/day prednisone (or equivalent) after 12 months of treatment with RoActemra/Actemra |  | approximately 29 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy: Disease activity score (DAS 28) |  | approximately 29 months | 
| Co-medications: dosage and treatment schedules |  | approximately 29 months | 
| Patient reported outcome: European League against Rheumatism - Rheumatoid Arthritis Impact of Disease score (EULAR-RAID)/Health Assessment Questionnaire - Disease Index (HAQ-DI) |  | approximately 29 months | 
| Safety: Incidence of adverse events |  | approximately 29 months |
Therapy Coil Electrogram Collection Study

Study Overview
=================
Brief Summary
-----------------
This is a prospective, non-randomized, multicenter, post market release study which will collect electrograms (EGMs) from patients at risk of a suspected insulation failure to the high voltage portion of the defibrillator lead and will evaluate the electrogram signals.

Official Title
-----------------
Therapy Coil Electrogram Collection Study

Conditions
-----------------
Lead Insulation Failure

Intervention / Treatment
-----------------
* Other: No treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is willing to sign and date the study Informed Consent form Subject is at least 18 years of age (or older, if required by local law) Subject is willing and able to wear a Holter monitor for up to 24 hours Subject has been implanted with a Medtronic ICD or CRT-D device Subject has an increased risk of lead insulation breach Exclusion Criteria: Subject has medical conditions that would limit study participation Subject is enrolled in one or more concurrent studies that would confound the results of this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No treatment<br> | Other: No treatment<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients With Abnormal Electrograms During a Lead Issue | Number of patients with at least one instance of abnormal noise during recording. Electrograms will be collected during 24 hours and afterwards abnormalities in the electrograms will be visually identified. | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of Patients With Abnormal Electrograms and Lead Failure | Compare the proportion of patients with abnormal electrograms (e.g. high frequency spike) and a high voltage lead failure within 1 month to those patients with abnormal electrograms and no lead failure within 1 month | 1 month | 
| Additional Abnormal Electrogram Characteristics | Identify additional characteristics in the Far-field Electrograms that may halp to identify patients at risk of a high voltage lead failure | 1 month |
Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to determine the efficacy and safety of topical application of LAS41003 in comparison to LAS189962 and LAS189961 in the treatment of superinfected eczema.

Official Title
-----------------
Explorative, Double-blind, Randomized, Controlled Multi-center Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41003 Once Daily Versus LAS189962 and LAS189961 in the Treatment of Superficial Infected Eczema

Conditions
-----------------
Eczema

Intervention / Treatment
-----------------
* Drug: LAS41003
* Drug: LAS189962
* Drug: LAS189961


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinically diagnosed super-infected or impetiginized eczema Exclusion Criteria: Patients who have general signs of systemic infections like fever, malaise, lymphangitis or swollen lymph nodes and / or need systemic antibiotic treatment Patients who have a bacterial skin infection which, due to depth and severity, could not be appropriately treated with a topical antimicrobial or antiseptic medication Diagnose of the following disease: Known active tuberculosis or any history of past tuberculosis of skin Suspected or proven parasitic infection of the treatment site (e.g. scabies) Psoriasis Suspected or proven viral infection of skin (e.g. Herpes) Localization of the superficial infected eczema: Palms of the hands Sole of a foot Face Have received any topical treatment with antibiotics, antimycotics, immunomodulators and corticosteroid preparations within the last 2 weeks before treatment with IMP

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LAS41003<br> | Drug: LAS41003<br>* Once daily, topically<br>|
| Active Comparator: LAS189962<br> | Drug: LAS189962<br>* Once daily, topically<br>|
| Active Comparator: LAS189961<br> | Drug: LAS189961<br>* Once daily, topically<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Combination of clinical and microbial treatment success |  | Day 14 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety:Physical examination at EoT, AEs/SAEs during the entire study |  | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Superficial infected eczema, Superinfected eczema